Lefamulin versus moxifloxacin for the treatment of community-acquired bacterial pneumonia. Results of a phase III trial.
Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial.
Rédigé par : Dr Jean-Pierre Bru
Lefamulin is a pleuromutilin antibiotic. Its name comes from the pleuromutilin-producing fungus Pleurotus mutilus. Previous pleuromutilin are already used : tiamulin and valnemulin were introduced to veterinary medicine in 1979 and 1999, and retapamulin was approved (FDA 2007) as a topical agent for the treatment of non-severe cutaneous infections.
Pleuromutilin inhibits bacterial protein synt...
Ce contenu est à destination des professionnels de santé. Merci de vous identifier.
This content is intended for healthcare professionals. Thank you for identifying yourself.
This content is intended for healthcare professionals. Thank you for identifying yourself.
Déjà inscrit / Already registered ?
Créer un compte / Create an account
Créer un compte ne prend que quelques minutes et vous permettra d'accèder à l'ensemble des contenus du site.
Creating an account takes only instant and will allow you to access all the content of the website.